Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton,Hope S. Rugo,Johannes Ettl,Sara A. Hurvitz,Anthony Gonçalves,Kyung Hun Lee,Louis Fehrenbacher,Rinat Yerushalmi,Lida A. Mina,Miguel Martin,Henri Roché,Young-Hyuck Im,Ruben G.W. Quek,Denka Markova,Iulia Cristina Tudor,Alison L. Hannah,Wolfgang Eiermann,Joanne L. Blum +17 more
TLDR
Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single‐agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression‐free survival.Abstract:
Background The poly(adenosine diphosphate–ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 (BRCA1/2). Methods We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician’s choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. Results Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% c...read more
Citations
More filters
Journal ArticleDOI
Breast Cancer Treatment: A Review.
Adrienne G. Waks,Eric P. Winer +1 more
TL;DR: This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer as well as distinct risk profiles and treatment strategies.
Journal ArticleDOI
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fatima Cardoso,Ana Costa,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,G. Bhattacharyya,Laura Biganzoli,Maria João Cardoso,Lisa A. Carey,D. Corneliussen-James,Giuseppe Curigliano,Véronique Diéras,N.S. El Saghir,Alex Eniu,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Alessandra Gennari,Nadia Harbeck,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Musa Mayer,H. Meijer,Shirley Mertz,S. Ohno,Olivia Pagani,E. Papadopoulos,Fedro A. Peccatori,Frédérique Penault-Llorca,Martine Piccart,Jean-Yves Pierga,Hope S. Rugo,Lillie D. Shockney,George W. Sledge,Sandra M Swain,Christoph Thomssen,Andrew Tutt,Daniel A. Vorobiof,Binghe Xu,Larry Norton,Eric P. Winer +44 more
TL;DR: This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients, and provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care.
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI
State-of-the-art strategies for targeting the DNA damage response in cancer
TL;DR: The authors review the progress made to date with PARP inhibitors, describe the expanding landscape of novel anticancer therapies targeting the DNA damage response and potential predictive biomarkers, mechanisms of resistance and combinatorial strategies are discussed.
Journal ArticleDOI
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F. Mosele,Jordi Remon,Joaquin Mateo,C. B. Westphalen,Fabrice Barlesi,Martijn P. Lolkema,Nicola Normanno,Aldo Scarpa,Mark E. Robson,Funda Meric-Bernstam,Nikhil Wagle,Albrecht Stenzinger,Julia Bonastre,A. Bayle,Stefan Michiels,Ivan Bièche,Etienne Rouleau,S. Jezdic,J.-Y. Douillard,Jorge S. Reis-Filho,R. Dienstmann,Fabrice Andre +21 more
TL;DR: ESMO recommends routine use of NGS on tumour samples in advanced non-squamous NSCLC, prostate cancers, ovarian cancers and cholangiocarcinoma, and develops multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development.
References
More filters
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Journal ArticleDOI
Interpreting the significance of changes in health-related quality-of-life scores.
TL;DR: The significance of changes in QLQ-C30 scores can be interpreted in terms of small, moderate, or large changes in quality of life as reported by patients in the SSQ.
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: This report is the first simple account yet published for non-statistical physicians of how to analyse efficiently data from clinical trials of survival duration, and it may be preferable to use these statistical methods to study time to local recurrence of tumour, or toStudy time to detectable metastatic spread, in addition to studying total survival.
Journal ArticleDOI
PARP inhibitors: Synthetic lethality in the clinic
TL;DR: Current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness are discussed, and interesting lessons for the development of other therapies are provided.
Journal ArticleDOI
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai,Shar Yin N. Huang,Benu Brata Das,Amelie Renaud,Yiping Zhang,James H. Doroshow,Jiuping Ji,Shunichi Takeda,Yves Pommier +8 more
TL;DR: This study shows that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA, providing a new mechanistic foundation for the rational application ofPARP inhibitors in cancer therapy.
Related Papers (5)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor Raza Mirza,Bradley J. Monk,Jørn Herrstedt,Amit M. Oza,Sven Mahner,Sven Mahner,Andrés Redondo,Michel Fabbro,Jonathan A. Ledermann,Domenica Lorusso,Ignace Vergote,Noa Ben-Baruch,Christian Marth,Radosław Mądry,René dePont Christensen,Jonathan S. Berek,Anne Dørum,Anne Dørum,Anna V. Tinker,Andreas du Bois,Antonio González-Martín,Philippe Follana,Benedict B. Benigno,Per Rosenberg,Lucy Gilbert,Bobbie J. Rimel,Joseph Buscema,John Balser,Shefali Agarwal,Ursula A. Matulonis,Ursula A. Matulonis +30 more